Search
HMI-103
go.drugbank.com/drugs/DB17684InvestigationalHMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.
Fludarabine
go.drugbank.com/drugs/DB01073ApprovedInvestigationalFludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
D-threo-neopterin
go.drugbank.com/drugs/DB02385Experimental(From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin. … A pteridine derivative present in body fluids; elevated levels result from immune system activation, malignant disease, allograft rejection, and viral infections.
YKP-1358
go.drugbank.com/drugs/DB06109ExperimentalIn addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects. … YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.
SB-509
go.drugbank.com/drugs/DB05579InvestigationalSB-509 is under investigation in multiple clinical trials for the treatment of Diabetic Neuropathy.
Thenalidine
go.drugbank.com/drugs/DB04826ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.
Synonyms: 1-Methyl-4-amino-N-phenyl-N-(2-thenyl)piperidine, 1-Methyl-4-N-2-thenylanilinopiperidineVapreotide
go.drugbank.com/drugs/DB04894InvestigationalVapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.
Eprinomectin
go.drugbank.com/drugs/DB11405ExperimentalVet approvedCategories: Compounds used in a research, industrial, or household settingDeltamethrin
go.drugbank.com/drugs/DB13600ExperimentalCategories: Compounds used in a research, industrial, or household settingIR208
go.drugbank.com/drugs/DB05106InvestigationalIt contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.